retatrutide nonalcoholic steatohepatitis trial Liraglutide safety and efficacy in patients with non-alcoholic (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Eli Lilly infiltrates anti-obesity market

Insurance will play a role in who is able to access retatrutide

Therefore, therapeutic interventions targeting the gastrointestinal system may benefit individuals suffering from brain fog symptoms

Knop et al., 2023

The first cohort included female patients who received a semaglutide or tirzepatide prescription during the study period

In the United States alone, the number of patients starting GLP-1 treatments for non-diabetic purposes has increased by 700% since 2019, with estimates suggesting that over 220,000 patients started treatment each month in 2024

For Wegovy, the STEP 1 trial found an average of approximately 10% by the same point